TRUE.CN Treatment.Com CNQ C$0.51 23 Mar 2026: Oversold bounce opportunity

TRUE.CN stock is trading at C$0.51 on the TSX Venture (CNQ) in Canada as of 23 Mar 2026, setting up a classic oversold bounce scenario after a five-day decline of -26.09%. Treatment.Com International Inc. (TRUE.CN) shows a small float, daily volume near 97,081.00 shares, and a market cap of C$38,506,224.00. With EPS -0.19 and price averages near the current level, short-term traders can spot a defined risk-reward where a relief rally is plausible. This note frames the technical entry, financial context, and Meyka AI grade for TRUE.CN stock to aid a measured oversold bounce strategy

TRUE.CN stock: Quick price snapshot and recent moves

TRUE.CN stock sits at C$0.51 after opening at C$0.51 and trading between C$0.51 and C$0.53 today on CNQ. Volume is 97,081.00 versus an average of 162,219.00, giving a relative volume of 0.60. The five-day drop of -26.09% is the key short-term trigger for an oversold bounce setup. The 50-day average is C$0.45 and the 200-day average is C$0.49, so the price sits just above the 200-day mean and below the 50-day mean, showing recent volatility and a rapid short-term selloff

TRUE.CN stock: Financials and valuation metrics

Treatment.Com International Inc. reports EPS -0.19 and a trailing PE of -2.68, reflecting losses and a thin revenue base. Price-to-sales is 73.52, price-to-book is 3.82, and gross margin is strong at 89.39%, while operating margin is negative at -15.86%. The current ratio is low at 0.09, and cash per share is C$0.00 (C$0.00 to two decimals). These figures signal weak liquidity and a high valuation multiple versus revenue, so any tactical bounce should be weighted by fundamental risk

TRUE.CN stock: Technical setup for an oversold bounce

The technical trigger for an oversold bounce is the steep short-term selloff: five-day change -26.09% and month-to-date decline -1.92% with year-to-date -15.00%. ATR is 0.03, indicating manageable intraday swings. Price sits near the 200-day average C$0.49 which can act as support. Traders looking for a bounce can target an initial recovery to the 50-day average C$0.45 (first resistance) and an intermediate target at the year high C$0.85 if momentum resumes. Use tight stops below recent lows to limit downside

TRUE.CN stock: Catalysts, risks and sector context

TRUE.CN operates in Healthcare, specifically Medical – Healthcare Information Services, a sector showing mixed performance in Canada. Broader healthcare headlines, including treatment persistence data for Alzheimer’s therapies, keep clinical-newsflow active source. Key risks for TRUE.CN stock are weak cash buffers, low current ratio, and tight float. Sector volatility from macro events can amplify moves; monitor market tone via major market coverage source

TRUE.CN stock: Meyka AI grade and analyst perspective

Meyka AI rates TRUE.CN with a score out of 100: 62.55 / Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The score reflects mixed fundamentals—strong gross margins but weak liquidity—and recent volatility. This grade is informational only and not investment advice. For full data and tracking, see the Meyka TRUE.CN page Meyka TRUE.CN page

TRUE.CN stock: Trade plan for an oversold bounce

A measured oversold-bounce plan for TRUE.CN stock: consider partial entry near C$0.51 with a stop loss at C$0.43 (about -15.69% from entry). Initial profit target C$0.68 (approx. +33.33% upside) with a secondary target at the year high C$0.85. Position size should reflect the high price-to-sales and poor current ratio. If price breaches C$0.40, treat the bounce attempt as failed and reassess fundamentals

Final Thoughts

TRUE.CN stock is presenting an oversold-bounce opportunity after a sharp five-day fall of -26.09% to C$0.51 on CNQ in Canada. The technical case rests on compressed volume, proximity to the 200-day average C$0.49, and a clear short-term range that offers defined risk. The fundamentals remain challenged: EPS -0.19, price-to-sales 73.52, and a current ratio of 0.09. Meyka AI’s forecast model projects a 12-month reference price of C$0.68, implying an upside of 33.33% versus the current price C$0.51; forecasts are model-based projections and not guarantees. For traders, a tight stop and small size are essential given liquidity and valuation risks. Investors should weigh the bounce trade against the company’s weak liquidity and high valuation, and monitor sector news and volume confirmation before adding exposure. Meyka AI provides this as an AI-powered market analysis platform perspective, not financial advice

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.